dipyridamole has been researched along with Cirrhosis in 6 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 7.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "Furthermore." | 5.30 | Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. ( De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C, 1999) |
| "In 34 patients with HCM, PET was performed using (13)N-labeled ammonia during hyperemia induced by intravenous dipyridamole." | 3.74 | Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. ( Betti, I; Camici, PG; Casolo, G; Cecchi, F; Olivotto, I; Pupi, A; Rega, L; Sciagrà , R; Sotgia, B, 2008) |
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 3.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "Furthermore." | 1.30 | Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. ( De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Grigoratos, C | 1 |
| Gueli, I | 1 |
| Arendt, CT | 1 |
| Leithner, D | 1 |
| Meloni, A | 1 |
| Nugara, C | 1 |
| Barison, A | 1 |
| Todiere, G | 1 |
| Puntmann, VO | 1 |
| Novo, G | 1 |
| Pepe, A | 1 |
| Emdin, M | 1 |
| Nagel, E | 1 |
| Aquaro, GD | 1 |
| Sotgia, B | 1 |
| Sciagrà , R | 1 |
| Olivotto, I | 1 |
| Casolo, G | 1 |
| Rega, L | 1 |
| Betti, I | 1 |
| Pupi, A | 1 |
| Camici, PG | 1 |
| Cecchi, F | 1 |
| Hung, KY | 2 |
| Huang, JW | 1 |
| Tsai, TJ | 2 |
| Hsieh, BS | 2 |
| Gervais, M | 1 |
| Richer, C | 1 |
| Fornes, P | 1 |
| De Gasparo, M | 1 |
| Giudicelli, JF | 1 |
| Shyu, RS | 1 |
| Fang, CC | 1 |
| Tsai, CC | 1 |
| Lee, PH | 1 |
| Boerboom, LE | 1 |
| Olinger, GN | 1 |
| Liu, TZ | 1 |
| Rodriguez, ER | 1 |
| Ferrans, VJ | 1 |
| Kissebah, AH | 1 |
1 review available for dipyridamole and Cirrhosis
| Article | Year |
|---|---|
Peritoneal fibrosing syndrome: pathogenetic mechanism and current therapeutic strategies.
Topics: Dipyridamole; Fibrosis; Humans; Pentoxifylline; Peritoneal Dialysis; Peritoneum; Risk Factors; Syndr | 2005 |
5 other studies available for dipyridamole and Cirrhosis
| Article | Year |
|---|---|
Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance.
Topics: Adenosine; Aged; Contrast Media; Dipyridamole; Female; Fibrosis; Heart Diseases; Humans; Magnetic Re | 2020 |
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Ammonia; Cardiomyopathy, Hypertrophic; Contrast Media; Coronary Circulation | 2008 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weigh | 1999 |
Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo.
Topics: Animals; Cell Adhesion; Cell Division; Cells, Cultured; Collagen; Cyclic AMP; Dipyridamole; Disease | 2001 |
Histologic, morphometric, and biochemical evolution of vein bypass grafts in a nonhuman primate model. III. Long-term changes and their modification by platelet inhibition with aspirin and dipyridamole.
Topics: Animals; Aspirin; Cholesterol; Dipyridamole; Drug Administration Schedule; Endothelium, Vascular; Fe | 1990 |